Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Q5VW
|
|||
| Former ID |
DNC003581
|
|||
| Drug Name |
L-778123
|
|||
| Synonyms |
183499-57-2; L-778123; UNII-31ZXM8ZKQ3; 4-[(5-{[4-(3-CHLOROPHENYL)-3-OXOPIPERAZIN-1-YL]METHYL}-1H-IMIDAZOL-1-YL)METHYL]BENZONITRILE; 31ZXM8ZKQ3; CHEMBL279433; 4-((5-((4-(3-chlorophenyl)-3-oxopiperazin-1-yl)methyl)-1H-imidazol-1-yl)methyl)benzonitrile; L-778123 free base; 4-[[5-[[4-(3-chlorophenyl)-3-oxopiperazin-1-yl]methyl]imidazol-1-yl]methyl]benzonitrile; 4-[(5-{[4-(3-chlorophenyl)-3-oxopiperazin-1-yl]methyl}imidazol-1-yl)methyl]benzonitrile; SCHEMBL1683541; AC1L50Q0; CTK7C7787; 1s63; 1s64; BDBM50097071; ZINC53070632
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Lymphoma [ICD-11: 2A80-2A86; ICD-9: 202.8, 208.9] | Phase 1 | [1], [2] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H20ClN5O
|
|||
| Canonical SMILES |
C1CN(C(=O)CN1CC2=CN=CN2CC3=CC=C(C=C3)C#N)C4=CC(=CC=C4)Cl
|
|||
| InChI |
1S/C22H20ClN5O/c23-19-2-1-3-20(10-19)28-9-8-26(15-22(28)29)14-21-12-25-16-27(21)13-18-6-4-17(11-24)5-7-18/h1-7,10,12,16H,8-9,13-15H2
|
|||
| InChIKey |
JNUGFGAVPBYSHF-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 183499-57-2
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Farnesyl protein transferase (Ftase) | Target Info | Modulator | [3] |
| Geranylgeranyl transferase I (GGTase-I) | Target Info | Modulator | [3] | |
| KEGG Pathway | Terpenoid backbone biosynthesis | |||
| Biosynthesis of antibiotics | ||||
| Reactome | Apoptotic cleavage of cellular proteins | |||
| Inactivation, recovery and regulation of the phototransduction cascade | ||||
| WikiPathways | Visual phototransduction | |||
| Apoptotic execution phase | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00003430) L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors. U.S. National Institutes of Health. | |||
| REF 2 | A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancer. Clin Cancer Res. 2004 Aug 15;10(16):5447-54. | |||
| REF 3 | Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein trans... Mol Cancer Ther. 2002 Jul;1(9):747-58. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.